Find a trial at the Pfizer Clinical Research Unit
3 trials found
A medical device containing 104 mg MPA (medroxyprogesterone acetate) in 0.65 mL suspension for injection and indicated for long-term female contraception via SC injection into the anterior thigh or abdomen every 13 weeks.
In this study the medication will be administrated subcutaneously (under the skin) in one of the following locations: arms, thigh or abdomen. During a subcutaneous injection, a needle is inserted under the skin, rather than into a vein.
The Pfizer Clinical Research Unit of Brussels will be conducting research studies in the near future with participants of Chinese descent.
This study will provide the basis for further clinical development of a Pfizer compound as a potential new, pharmacological agent for the treatment of ulcerative colitis.
Interested in participating?
Either dial the toll-free number 00800/2636 2636 (from Belgium, France, Germany, The Netherlands, Italy, and Japan) or +32 2 566 78 46 (from other countries) and speak with a representative of the PCRU to learn more. Alternatively, click here to see if you may qualify for our research unit’s ongoing clinical trials.